Pediatric oncology nursing advanced clinical handbook
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Berlin[u.a.]
Springer
2010
|
| Ausgabe: | 2. ed. |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV035826352 | ||
| 003 | DE-604 | ||
| 005 | 20100111 | ||
| 007 | t| | ||
| 008 | 091113s2010 gw ad|| |||| 00||| eng d | ||
| 015 | |a 09,N30,0634 |2 dnb | ||
| 016 | 7 | |a 995195560 |2 DE-101 | |
| 020 | |a 9783540879831 |c GB. : EUR 106.95 (freier Pr.), sfr 155.50 (freier Pr.) |9 978-3-540-87983-1 | ||
| 024 | 3 | |a 9783540879831 | |
| 028 | 5 | 2 | |a 12210930 |
| 035 | |a (OCoLC)505238428 | ||
| 035 | |a (DE-599)DNB995195560 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BE | ||
| 049 | |a DE-355 | ||
| 050 | 0 | |a RC281.C4 | |
| 082 | 0 | |a 618.929940231 |2 22 | |
| 084 | |a XH 2316 |0 (DE-625)152878:12922 |2 rvk | ||
| 084 | |a 610 |2 sdnb | ||
| 245 | 1 | 0 | |a Pediatric oncology nursing |b advanced clinical handbook |c Deborah Tomlinson ... (eds.) |
| 250 | |a 2. ed. | ||
| 264 | 1 | |a Berlin[u.a.] |b Springer |c 2010 | |
| 300 | |a XXI, 584 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Child | |
| 650 | 4 | |a Neoplasms |x nursing | |
| 650 | 4 | |a Nursing Care |x methods | |
| 650 | 4 | |a Pediatric Nursing |x methods | |
| 650 | 4 | |a Pediatric nursing | |
| 650 | 4 | |a Tumors in children |x Nursing | |
| 650 | 0 | 7 | |a Kind |0 (DE-588)4030550-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krankenpflege |0 (DE-588)4032813-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Kind |0 (DE-588)4030550-8 |D s |
| 689 | 0 | 1 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 2 | |a Krankenpflege |0 (DE-588)4032813-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Tomlinson, Deborah |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018684989&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-018684989 | |
Datensatz im Suchindex
| DE-BY-UBR_call_number | 91/XH 2316 T659(2) 938/XH 2316 T659(2) |
|---|---|
| DE-BY-UBR_katkey | 4543800 |
| DE-BY-UBR_location | 91 |
| DE-BY-UBR_media_number | 069036354945 TEMP12188325 |
| _version_ | 1822756530550734848 |
| adam_text | Contents
PARTI
1
Leukemia
Sue Zupanec
·
Deborah Tomlinson
1.1
Introduction
....................... 2
1.2
Acute Lymphoblastk
Leukemia
..........
З
1.2.1
Epidemiology
..................
З
1.2.2
Etiology
...................... 4
1.2.3
Molecular Genetics
............... 6
1.2.4
Symptoms and Clinical Signs
........ 7
1.2.5
Diagnostics
................... 8
1.2.6
Staging and Classification
.......... 9
1.2.7
Treatment
.................... 12
1.2.8
Prognosis
..................... 16
1.2.9
Follow-Up
.................... 16
1.2.10
Future Perspectives
.............. 17
1.2.11
RelapsedALL
.................. 17
1.3
Acute Myeloid Leukemia
............... 19
1.3.1
Epidemiology
.................. 19
1.3.2
Etiology
...................... 19
1.3.3
Molecular Genetics
............... 20
1.3.4
Symptoms and Clinical Signs
........ 20
1.3.5
Diagnostics
................... 21
1.3.6
Staging and Classification
.......... 21
1.3.7
Treatment
.................... 22
1.3.8
Prognosis
..................... 24
1.3.9
Follow-Up
.................... 24
1.3.10
Future Perspectives
.............. 24
1.4
Chronic Myeloid Leukemia
.............. 25
1.4.1
Epidemiology and Etiology
......... 25
1.4.2
Molecular Genetics
............... 25
1.4.3
Symptoms and Clinical Signs
........ 25
1.4.4
Diagnostics
................... 26
1.4.5
Treatment
.................... 26
1.4.6
Prognosis
..................... 26
1.4.7
Future Perspectives
.............. 26
1.5
Juvenile Myelomonocytic Leukemia
....... 26
1.6 Langerhans
Cell Histiocytosis
............ 27
1.6.1
Epidemiology and Etiology
......... 27
1.6.2
Diagnostics
................... 28
1.6.3
Symptoms and Clinical Signs
........ 28
1.6.4
Treatment
.................... 29
1.6.5
Prognosis
..................... 29
References
............................. 29
2
Lymphoma
Sue Zupanec
2.1
Lymphoma
........................ 33
2.2
Hodgkin
Lymphoma
.................. 33
2.2.1
Epidemiology
.................. 34
2.2.2
Etiology
...................... 34
2.2.3
Molecular Genetics
............... 34
2.2.4
Symptoms and Clinical Signs
........ 34
2.2.5
Diagnostics
................... 36
2.2.6
Staging and Classification
.......... 38
2.2.7
Treatment
.................... 39
2.2.8
Prognosis
..................... 42
2.2.9
Follow-Up
.................... 43
2.2.10
Relapsed/Refractory HL
............ 43
2.2.11
Future Perspectives
.............. 44
2.3
Non-Hodgkin Lymphomas
.............. 44
2.3.1
Epidemiology
.................. 44
2.3.2
Etiology
...................... 45
2.3.3
Molecular Genetics
............... 45
2.3.4
Symptoms and Clinical Signs
........ 46
2.3.5
Diagnostics
................... 48
2.3.6
Staging and Classification
.......... 50
2.3.7
Treatment
.................... 50
2.3.8
Prognosis
..................... 54
2.3.9
Follow-Up
.................... 54
2.3.10
Treatment of Relapsed/Refractory NHL
. 55
2.3.11
Future Perspectives
.............. 55
References
............................. 56
3
Solid Tumor
Eleanor Hendershot
3.1
Ewing s Sarcoma Family of Tumors
........ 60
3.1.1
Epidemiology
.................. 60
3.1.2
Etiology
...................... 60
3.1.3
Molecular Genetics
............... 60
3.1.4
Symptoms and Clinical Signs
........ 61
3.1.5
Diagnosis
..................... 61
3.1.6
Staging and Classification
.......... 63
3.1.7
Treatment
.................... 63
3.1.8
Prognosis
..................... 64
Contents
3.1.9
Follow-Up
.................... 65
3.1.10
Future Perspectives
.............. 65
3.2
Osteosarcoma
...................... 65
3.2.1
Epidemiology
.................. 66
3.2.2
Etiology
...................... 66
3.2.3
Molecular Genetics
............... 66
3.2.4
Signs and Symptoms
............. 67
3.2.5
Diagnostics
................... 67
3.2.6
Staging and Classification
.......... 68
3.2.7
Treatment
.................... 68
3.2.8
Prognosis
..................... 71
3.2.9
Follow-Up
.................... 71
3.2.10
Future Perspectives
.............. 71
3.3
Liver Tumors
....................... 72
3.3.1
Epidemiology
.................. 72
3.3.2
Etiology
...................... 72
3.3.3
Molecular Genetics
............... 72
3.3.4
Symptoms and Clinical Signs
........ 72
3.3.5
Diagnostics
................... 73
3.3.6
Staging and Classification
.......... 74
3.3.7
Treatment
.................... 75
3.3.8
Prognosis
..................... 76
3.3.9
Follow-Up
.................... 76
3.3.10
Future Perspectives
.............. 77
3.4
Neuroblastoma
..................... 77
3.4.1
Epidemiology
.................. 77
3.4.2
Etiology
...................... 77
3.4.3
Molecular Genetics
............... 77
3.4.4
Symptoms and Clinical Signs
........ 79
3.4.5
Diagnostics
................... 80
3.4.6
Staging and Classification
.......... 81
3.4.7
Treatment
.................... 82
3.4.8
Prognosis
..................... 85
3.4.9
Follow-Up
.................... 85
3.4.10
Future Perspectives
.............. 86
3.5
Renal Tumors
....................... 86
3.5.1
Epidemiology
.................. 86
3.5.2
Etiology
...................... 87
3.5.3
Molecular Genetics
............... 87
3.5.4
Symptoms and Clinical Signs
........ 87
3.5.5
Diagnostics
................... 88
3.5.6
Staging and Classification
.......... 89
3.5.7
Treatment
.................... 89
3.5.8
Prognosis
..................... 92
3.5.9
Follow-Up
.................... 93
3.5.10
Future Perspectives
.............. 93
3.6
Retinoblastoma
..................... 93
3.6.1
Epidemiology
.................. 93
3.6.2
Etiology
...................... 94
3.6.3
Molecular Genetics
............... 94
3.6.4
Signs and Symptoms
............. 94
3.6.5
Diagnostics
................... 95
3.6.6
Staging and Classification
.......... 96
3.6.7
Treatment
.................... 96
3.6.8
Prognosis
..................... 99
3.6.9
Follow-Up
....................100
3.6.10
Future Directions
................100
3.7
Rhabdomyosarcoma
..................100
3.7.1
Epidemiology
..................100
3.7.2
Etiology
......................101
3.7.3
Molecular Genetics
...............101
3.7.4
Symptoms and Clinical Signs
........101
3.7.5
Diagnostics
...................101
3.7.6
Staging and Classification
..........103
3.7.7
Treatment
....................103
3.7.8
Prognosis
.....................106
3.7.9
Follow-Up
....................106
3.7.10
Future Perspectives
..............106
3.8
Non-Rhabdomyosarcomatous
Soft-Tissue Sarcomas
.................107
3.8.1
Alveolar Soft-Part Sarcoma
..........108
3.8.2
Desmoid Tumor (Aggressive
Fibromatosis)
..................108
3.8.3
Desmoplastic Small Round Cell Tumor
. . 108
3.8.4
Infantile
Fibrosarcoma
............109
3.8.5
Infantile Hemangiopericytoma
.......109
3.8.6
Infantile Myofibromatosis
..........109
3.8.7
Leiomyosarcoma
................109
3.8.8
Liposarcoma
...................109
3.8.9
Malignant Peripheral Nerve
Sheath Tumor
.................110
3.8.10
Synovial
Sarcoma
...............110
3.9
Germ Cell Tumors
...................110
3.9.1
Epidemiology
..................111
3.9.2
Etiology
......................111
3.9.3
Molecular Genetics
...............112
3.9.4
Symptoms and Clinical Signs
........112
3.9.5
Diagnostics
...................112
3.9.6
Staging and Classification
..........113
3.9.7
Treatment
....................113
3.9.8
Prognosis
.....................115
3.9.9
Follow-Up
....................115
3.9.10
Future Perspectives
..............116
3.10
Rare Tumors
.......................116
3.10.1
Adrenocortical Carcinoma
..........116
3.10.2
Melanoma
....................117
3.10.3
Nasopharyngeal Carcinoma
.........118
3.10.4
Pleuropulmonary
Blastoma
.........118
3.10.5
Thyroid Carcinoma
...............119
References
.............................119
4
Central Nervous System Tumors
Nancy E. Kline
·
Joan O Hanlon-Curry
4.1
Causes/Epidemiology
.................129
4.2
Distribution/Classification
..............129
4.3
Staging
...........................
і зо
4.4
Molecular Genetics of Brain Tumors
.......130
Contents
4.5
Diagnosis
.........................130
4.6
Specialist Referral
....................130
4.7
Hydrocephalus
......................130
4.8
Treatment
.........................131
4.8.1
Surgery
......................131
4.8.2
Radiotherapy
..................131
4.8.3
Chemotherapy
.................132
4.9
Prognosis
.........................132
4.10
Specific Tumors
.....................132
4.10.1
PNETs/Medulloblastomas
..........132
4.10.2
Astrocytomas/Glial Tumors
.........133
4.10.3
Malignant Gliomas
...............134
4.10.4
Other High-Grade Gliomas
..........134
4.11
Follow-Up
.........................138
4.11.1
The Late Effects and Rehabilitation
of Survivors
...................138
4.11.2
Palliative Care
..................139
4.11.3
Future Perspectives/New Innovations
..139
References
.............................140
PART II
5
Anemias
Rosalind Bryant
5.1
Anemia
...........................142
5.2
Iron-Deficiency Anemia
................146
5.2.1
Epidemiology
.................. 146
5.2.2
Etiology
...................... 146
5.2.3
Molecular Genetics
............... 146
5.2.4
Symptoms/Clinical Signs
........... 146
5.2.5
Diagnostic Testing
............... 147
5.2.6
Treatment
.................... 148
5.2.7
Transfusion
................... 148
5.2.8
Erythropoietin (Epogen)
........... 148
5.2.9
Prognosis
..................... 149
5.3
Sickle Cell Disease
................... 149
5.3.1
Epidemiology
..................149
5.3.2
Etiology
......................149
5.3.3
Molecular Genetics
...............149
5.3.4
Symptoms/Clinical Signs
...........149
5.3.5
Diagnostic Testing
...............150
5.3.6
Complications of SCD
.............151
5.3.7
Prognosis
.....................158
5.3.8
Future Perspectives
..............158
5.4
Thalassemia
........................158
5.4.1
Alpha (a)-Thalassemia
............158
5.4.2
Beta Thalassemia (Cooley Anemia)
.....159
5.4.3
Diagnostic Testing
...............160
5.4.4
Treatment
....................160
5.4.5
Treatment of Hemosiderosis
(Iron Overload)
.................160
5.4.6
Chelation Therapy
...............161
5.4.7
Clinical Advances (Hemosiderosis)
.....161
5.4.8
Prognosis
.....................161
5.4.9
Follow-Up
....................162
5.4.10
Future Perspectives
..............162
5.5.
Hemolytic Anemia
...................162
5.5.1
Hereditary Spherocytosis
..........162
5.5.2
Autoimmune Hemolytic Anemia
.....164
5.5.3 Glucose-ö-Phosphate Dehydrogenase
Deficiency
....................165
5.6
Bone Marrow Failure Syndromes
.........167
5.6.1
Aplastic Anemia
................167
References
.............................170
6
Neutropenia
Karyn
Brandige
6.1
Epidemiology
.......................173
6.2
Etiology
..........................174
6.3
Symptoms and Clinical Signs
............175
6.4
Diagnostic Testing
...................175
6.5
Treatment
.........................176
6.6
Prognosis
.........................177
6.7
Follow-Up
.........................178
References
.............................178
7
Thrombocytopenia
Karyn
Brandige
7.1
Epidemiology
.......................179
7.2
Etiology
..........................180
7.3
Symptoms and Clinical Signs
............180
7.4
Diagnostic Testing
...................182
7.5
Treatment
.........................182
7.6
Prognosis
.........................184
7.7
Follow-Up
.........................184
7.8
Future Perspectives
..................184
References
.............................184
8
Bleeding Disorders
Joan O Brien-Shea
8.1
Hemophilia
........................187
8.1.1
Epidemiology
..................187
8.1.2
Etiology
......................187
8.1.3
Genetics
.....................188
8.1.4
Symptoms and Clinical Signs
........188
8.1.5
Diagnostic Testing
...............190
8.1.6
Treatment
....................191
8.1.7
Prognosis
.....................194
8.1.8
Follow-Up
....................194
Contents
8.1.9
Future
Perspectives
..............194
8.2 von Willebrand
Disease
................194
8.2.1
Epidemiology
..................194
8.2.2
Etiology
......................195
8.2.3
Genetics
.....................195
8.2.4
Symptoms and Clinical Signs
........195
8.2.5
Diagnostic Testing
...............196
8.2.6
Treatment
....................199
8.2.7
Prognosis
.....................200
8.2.8
Follow-Up
....................200
References
.............................201
PART 111
9
Chemotherapy
Christine Chordas
·
Kristen
Graham
9.1
Introduction
.......................204
9.2
Cancer Cell Characteristics
..............204
9.2.1
The Cell Cycle
..................204
9.2.2
Cell Cycle Control
................205
9.3
Chemotherapy
......................206
9.3.1
Principles
.....................206
9.3.2
Resistance
....................206
9.3.3
The Principles of Pharmacokinetics,
Pharmacodynamics,
and Pharmacogenomics
...........206
9.3.4
Chemotherapy Techniques
.........207
9.4
Clinical Trials
.......................207
9.4.1
Phase I Clinical Trials
..............208
9.4.2
Phase II Clinical Trials
.............208
9.4.3
Phase III Clinical Trials
.............208
9.4.4
Phase IV Clinical Trials
.............208
9.5
Chemotherapy Agents
................208
9.5.1
Antimetabolites
.................211
9.5.2
Alkylating Agents
...............216
9.5.3
Antitumor
Antibiotics
.............217
9.5.4
Anthracycline Antibiotics
...........218
9.5.5
Plant Derivatives
................218
9.5.6
Antiangiogenic Agents
............219
9.5.7
Miscellaneous Agents
.............220
9.6
Chemotherapy Protectants
.............221
9.6.1
Allopurinol (Zyloprim)
.............221
9.6.2
Amifostine (Ethyol)
...............221
9.6.3
Dexrazoxane (Zinecard)
...........221
9.6.4
Leucovorin Calcium (LCV, Wellcovorin,
Citovorum Factor,
Folie Acid)
........221
9.6.5
Mesna
(Mesnex)
................221
9.6.6
Palifermin
....................222
9.7
Administration of Chemotherapy Agents.
. . . 222
9.7.1
Preparation
...................222
9.7.2
Administration and Practice
Considerations
.................223
9.8
Professional Guidelines to Minimize
the Risk of Medication Errors
............224
9.8.1
Prescribing Errors
................224
9.9
Safe Practice Considerations
............224
9.9.1
Mixing Chemotherapeutic Agents
.....225
9.9.2
Transporting Cytotoxic Agents
.......225
9.9.3
Safe Handling After Chemotherapy
.... 225
9.9.4
Disposal of Cytotoxic Materials
.......225
9.9.5
Spill Management
...............226
9.9.6
Procedures Following Accidental
Exposure
.....................226
9.9.7
Storage
......................226
9.9.8
Medical Management
.............226
9.10
Administration of Chemotherapy
in the Home
........................226
9.11
Immediate Complications of Chemotherapy
Administration
......................226
9.11.1
Extravasation
..................227
9.11.2
Acute Hypersensitivity Reactions
(HSRs) to Chemotherapy
...........230
9.11.3
Risk Factors for Hypersensitivity,
Flare Reactions, or Anaphylaxis
.......230
9.11.4
Recommended Steps to
Prevent HSRs
..................230
9.11.5
Emergency Management of
HSR/Anaphylaxis
................230
9.12
Summary
..........................231
References
.............................231
10
Radiotherapy
Irene Loch
·
Jane Khorrami
10.1
Introduction
.......................233
10.2
Radiation
.........................233
10.3
Principles of Treatment
................234
10.4
Treatment Planning
..................234
10.4.1
CT Simulation
..................234
10.4.2
Simulation
....................234
10.5
Treatment Methods
..................235
10.5.1
External Beam Radiotherapy
(Teletherapy)
..................235
10.5.2
Fractionation
..................237
10.5.3
Total Body Irradiation (TBI)
..........237
10.5.4
Brachytherapy
..................237
10.5.5
Sealed Sources
.................237
10.5.6
Unsealed Sources
...............237
10.6
Side Effects of Radiotherapy
............238
10.6.1
Acute Effects
...................238
10.7
Special Considerations
................240
10.7.1
Preparation of Children
and Young People
...............240
10.8
Future Perspectives
..................240
10.8.1
Image-Guided Radiotherapy
........240
Contents
10.8.2 Intra-Operative
Radiotherapy
........240
10.8.3 Proton
Radiotherapy (PRT)
..........240
References.............................
241
11 Hematopoietic Stem
Cell
Transplantation
Robbie Norville ·
Deborah
Tomiimon
11.1
Principles of Treatment
................243
11.2
Stem Cell Collection (Harvest)
...........244
11.2.1
Bone Marrow Stem Cells
...........244
11.2.2
Peripheral Blood Stem Cells
.........246
11.2.3
Umbilical Cord Blood
Stem Cells
....................246
11.3
Donor Stem Cell Typing/
Tissue Typing
.......................247
11.4
Donor Stem Cell Sources
...............248
11.5
Stem Cell Processing and
Infusion
...........................249
11.5.1
ABO Mismatch
.................249
11.5.2
Graft vs. Leukemia
...............251
11.6
Description of Treatment
...............251
11.7
Potential Side Effects
.................253
11.7.1
Early Side Effects
................253
11.7.2
Intermediate Side Effects
...........257
11.7.3
Late Side Effects
................261
11.8
Special Considerations
................263
11.9
Future Perspectives
..................264
References
.............................265
12
Surgical Approaches
to Childhood Cancer
Carol L.
Rossetto
12.1
Principles of Treatment
................269
12.2
Method of Delivery
...................270
12.2.1
Preoperative
Evaluation
...........270
12.2.2
Postoperative Nursing Care
.........271
12.3
Potential Side Effects
.................271
12.3.1
Complications of Medical Therapy
Requiring Surgical Evaluation
........271
12.3.2
Complications Arising from Surgical
Management of Solid Tumors
........272
12.4
Special Considerations
................273
12.4.1
Vascular Access Devices
...........273
12.5
Future Perspectives
..................274
12.5.1
New Surgical Techniques and
Directions for Future Research
.......274
References
.............................275
13
Cell and Gene Therapy
Robbie Norville
13.1
Introduction
.......................277
13.2
Principles of Treatment
................278
13.2.1
Genetic Deficit Repair
.............278
13.2.2
Viral-Mediated Gene Transfer
........278
13.2.3
Drug-Resistant Genes
.............278
13.2.4
Angiogenetics Inhibitors
...........279
13.2.5
Gene Marking
..................279
13.2.6
Cell Therapy
...................279
13.3
Method of Delivery
...................279
13.3.1
Viral Vectors
...................280
13.3.2
Plasmid Vectors
.................280
13.4
Potential Side Effects
.................280
13.5
Special Considerations
................281
13.6
Future Perspectives
..................281
References
.............................281
14
Biological and Targeted Therapies
Lindsay Gainer
14.1
Introduction
.......................283
14.2
Principles of Treatment
................284
14.3
Description of Treatment
...............285
14.3.1
Cytokines
.....................285
14.3.2 Interferons....................285
14.3.3
Interleukins
...................286
14.3.4
Colony-stimulating Factors
.........286
14.3.5
Fusion Proteins
.................286
14.3.6
Monoclonal Antibodies
............287
14.4
Cancer Vaccines
.....................288
14.5
Other Immunomodulating Agents
........288
14.5.1
Nonspecific Immunomodulating
Agents
......................288
14.5.2
Retinoids
.....................289
14.5.3
Thalidomide
...................289
14.6
Adoptive Immunotherapy
..............289
14.7
Molecular Targeted Therapy
............289
14.8
Method of Delivery
...................290
14.9
Potential Side Effects
.................291
14.10
Future Perspectives
..................292
References
.............................293
15
Complementary and Alternative
Medicine
Janice Post-White
·
Elena
Ladas
15.1
15.2
Introduction
. .
CAM Modalities
295
.296
Contents
15.2.1
Acupuncture
..................296
15.2.2
Biological Therapies
..............297
15.2.3
Mind-Body Therapies
.............299
15.2.4
Movement Therapies
.............300
15.2.5
Aromatherapy
..................301
15.2.6
Massage
.....................302
15.2.7
Energy Therapies
................303
15.3
Future Perspectives
..................303
References
.............................304
16
Clinical Trials
Biljana Dzolganovski
16.1
The Role of Clinical Trials
...............307
16.1.1
The Need for Research
............307
16.1.2
Phases of Clinical Trials
............308
16.1.3
Study Types
...................308
16.1.4
Research Ethics: Principles, Policies,
and Guidelines
.................308
16.1.5
Legal and Ethical Issues Regarding
Participation of Children in Research
. . . 310
16.1.6
Research in Pediatrics
.............312
16.2
Research Networks
...................312
16.2.1
Cooperative Group Research
........312
16.2.2
Importance of Participation in
Clinical Trials
...................314
16.3
Progress Made Through Clinical Trials
......315
16.3.1
Treatments and Therapy Delivery
.....315
16.3.2
Quality of Life Measures and
Supportive Care
................319
16.3.3
Complementary and Alternative
Medicine
.....................320
16.3.4
Late Effects
....................321
16.3.5
Palliative Care
..................321
16.4
Perception of Clinical Trials
.............322
16.5 Future of Clinical Trials
................324
16.6
The Role of the Clinical Research Associate
. . 324
16.6.1
Introduction
...................324
16.6.2
Clinical Research Associate
.........325
16.6.3
The Role of the CRA
..............326
16.6.4
The Role of the Clinical Research
Nurse
.......................328
References
.............................329
PART IV
17
Metabolic System
Deborah Tomlinson
17.1
Cancer Cachexia
.....................337
17.1.1
incidence
.....................337
17.1.2
Etiology
......................338
17.1.3
Treatment
....................338
17.1.4
Prognosis
.....................339
17.2
Obesity
...........................339
17.2.1
Obesity in Survivors of Leukemia
......339
17.3
Inferior Outcomes and Obesity
...........340
17.3.1
Incidence
.....................340
17.3.2
Etiology
......................341
17.4
Tumor Lysis Syndrome
................341
17.4.1
Incidence
.....................341
17.4.2
Etiology
......................341
17.4.3
Treatment
....................343
17.4.4
Prognosis
.....................347
17.5
Hypercalcemia
......................347
17.5.1
Incidence
.....................347
17.5.2
Etiology
......................347
17.5.3
Treatment
....................347
17.5.4
Prognosis
.....................348
17.6
Impaired Glucose Tolerance
.............348
17.6.1
Incidence
.....................348
17.6.2
Etiology
......................348
17.6.3
Treatment
....................349
17.6.4
Prognosis
.....................349
References
.............................349
18
Gastrointestinal Tract
Anne Marie Maloney
18.1
Mucositis
..........................354
18.1.1
Incidence
.....................354
18.1.2
Etiology
......................354
18.1.3
Prevention
....................357
18.1.4
Treatment
....................357
18.1.5
Prognosis
.....................358
18.2
Dental Caries
.......................358
18.2.1
incidence
.....................358
18.2.2
Etiology
......................358
18.2.3
Prevention and Treatment
..........359
18.2.4
Prognosis
.....................359
18.3
Nausea and Vomiting
.................359
18.3.1
Incidence
.....................359
18.3.2
Etiology
......................359
18.3.3
Prevention
....................360
18.3.4
Treatment
....................360
18.3.5
Delayed Nausea and Vomiting
.......361
18.3.6
Anticipatory Nausea and Vomiting
.... 361
18.3.7
Radiation-Induced Nausea and Vomiting.
. 362
18.3.8
Other Causes of Nausea and Vomiting
. . 363
18.3.9
Nonpharmacoiogical Management
.... 363
18.3.10
Prognosis
.....................364
18.4
Constipation
.......................364
18.4.1
Incidence
.....................364
18.4.2
Etiology
......................364
18.4.3
Prevention
....................365
18.4.4
Treatment
....................365
18.4.5
Prognosis
.....................366
Contents
18.5
Diarrhea
..........................366
18.5.1
Incidence
.....................366
18.5.2
Etiology
......................366
18.5.3
Prevention
....................368
18.5.4
Treatment
....................368
18.5.5
Prognosis
.....................369
18.6
Typhylitis
.........................369
18.6.1
Incidence
.....................369
18.6.2
Etiology
......................370
18.6.3
Prevention
....................370
18.6.4
Treatment
....................370
18.6.5
Prognosis
.....................371
18.7
Perirectal
Cellulitis
...................371
18.7.1
Incidence
.....................371
18.7.2
Etiology
......................371
18.7.3
Prevention
....................371
18.7.4
Treatment
....................371
18.7.5
Prognosis
.....................372
18.8
Acute Gastrointestinal Graft Vs.
Host Disease
.......................372
18.8.1
Incidence
.....................372
18.8.2
Prevention
....................372
18.8.3
Treatment
....................373
18.8.4
Prognosis
.....................374
18.9
Chemical Hepatitis
...................374
18.9.1
Incidence
.....................374
18.9.2
Etiology
......................374
18.9.3
Prevention
....................374
18.9.4
Treatment
....................374
18.9.5
Prognosis
.....................375
18.10
Pancreatitis
........................375
18.10.1
Incidence
.....................375
18.10.2
Etiology
......................375
18.10.3
Prevention
....................375
18.10.4
Treatment
....................375
18.10.5
Prognosis
.....................375
References
.............................376
19
Bone Marrow Function
Sandra Doyle
19.1
Introduction
.......................380
19.2
Anemia
...........................380
19.2.1
Incidence and Etiology
............380
19.2.2
Treatment
....................380
19.3
Neutropenia
.......................381
19.3.1
Incidence and Etiology
............381
19.3.2
Treatment
....................382
19.4
Thrombocytopenia
...................389
19.4.1
Incidence and Etiology
............389
19.4.2
Treatment
....................389
19.5
Transfusion Issues
...................390
19.5.1
Granulocyte Transfusions
..........390
19.5.2
Transfusion-Associated Graft vs. Host
Disease
......................391
19.5.3
Cytomegalovirus and Transfusions
.... 392
19.5.4
Platelet Refractoriness
............392
19.6
Disseminated
Intravascular
Coagulation
.... 393
19.6.1
Etiology and Manifestation
.........393
19.6.2
Treatment
....................394
19.7
Septic Shock
.......................395
19.7.1
Etiology
......................395
19.7.2
Treatment
....................395
19.7.3
Prognosis
.....................396
19.8
Immune Suppression
.................396
19.8.1
Polymorphonudear Leukocytes
......396
19.8.2
Lymphocytes
..................397
19.8.3
Spleen and Reticuloendothelial System
. 398
19.8.4
Other Factors Contributing
to Immunocompromised States
......398
References
.............................398
20
Respiratory System
Margaret Parr
20.1
Pneumocystis Pneumonia
..............401
20.1.1
Incidence
.....................401
20.1.2
Etiology
......................402
20.1.3
Treatment
....................402
20.1.4
Prognosis
.....................404
20.2
Pneumonitis
.......................404
20.2.1
Incidence
.....................404
20.2.2
Etiology
......................404
20.2.3
Prevention
....................405
20.2.4
Treatment
....................405
20.2.5
Prognosis
.....................405
20.3
Fibrosis
...........................406
20.3.1
Incidence
.....................406
20.3.2
Etiology
......................406
20.3.3
Prevention
....................406
20.3.4
Treatment
....................406
20.3.5
Prognosis
.....................406
20.4
Compromised Airway
.................407
20.4.1
Incidence
.....................407
20.4.2
Etiology
......................407
20.4.3
Prevention
....................407
20.4.4
Treatment
....................408
20.4.5
Prognosis
.....................408
References
.............................408
21
Renal System
Fiona Reid
21.1
Nephrectomy
.......................412
21.1.1
Incidence
.....................412
21.1.2
Etiology
......................412
21.1.3
Treatment
....................412
21.1.4
Prognosis
.....................416
Contents
21.2
Cytotoxic Drug Excretion
...............417
21.2.1
Pharmacokinetics/Dynamics
........417
21.2.2
Metabolism
...................418
21.2.3
Excretion
.....................418
21.2.4
Drug Interactions
................420
21.2.5
Dose Modification
...............420
21.2.6
Safe Handling of Cytotoxic Excreta
....424
21.3
Nephrotoxicity
......................425
21.3.1
Incidence
.....................425
21.3.2
Etiology
......................426
21.3.3
Prevention
....................427
21.3.4
Treatment
....................430
21.3.5
Prognosis
.....................432
21.4
Hemorrhagic Cystitis
..................432
21.4.1
Incidence
.....................432
21.4.2
Etiology
......................433
21.4.3
Prevention
....................434
21.4.4
Treatment
....................435
21.4.5
Prognosis
.....................437
References
.............................437
22
Cardiovascular System
Alison Hall
22.1
Cardiac
Toxicity
/Cardiomyopathy
.........441
22.1.1
Incidence
.....................441
22.1.2
Etiology
......................443
22.1.3
Treatment
....................445
22.1.4
Prevention
....................445
22.1.5
Prognosis
.....................447
22.2
Veno-Occlusive Disease
................447
22.2.1
Hepatic Veno-Occlusive Disease
......447
22.2.2
Pulmonary Veno-Occlusive Disease
.... 449
References
.............................450
23
Central Nervous System
Jane Belmore
·
Deborah Tomlinson
23.1
Spinal Cord Compression
...............453
23.1.1
Incidence
.....................453
23.1.2
Etiology
......................453
23.1.3
Treatment
....................454
23.1.4
Prognosis
.....................454
23.2
Fatigue
...........................454
23.2.1
Incidence
.....................455
23.2.2
Etiology
......................455
23.2.3
Treatment
....................456
23.2.4
Prognosis
.....................457
23.3
Cognitive Deficits
....................458
23.3.1
Incidence
.....................458
23.3.2
Etiology
......................458
23.3.3
Prevention and Treatment
..........458
23.3.4
Prognosis
.....................459
23.4
Diabetes Insipidus
...................459
23.4.1
Incidence
.....................459
23.4.2
Etiology
......................460
23.4.3
Treatment
....................460
23.4.4
Prognosis
.....................460
References
.............................460
24
Musculoskeletal System
Deborah Tomlinson
·
SueZupanec
24.1
Bone Tumors
.......................463
24.1.1
Limb Salvage Procedures
...........463
24.1.2
Amputation
...................464
24.1.3
Comparison of Limb Salvage and
Amputation
...................469
24.2
Altered Bone Mineral Densityand
Increased Fracture Risk
................470
24.2.1
Incidence
.....................470
24.2.2
Etiology
......................471
24.2.3
Prevention and Treatment
..........471
24.2.4
Prognosis
.....................472
24.3
Osteonecrosis
......................472
24.3.1
Incidence
.....................473
24.3.2
Etiology
......................474
24.3.3
Treatment
....................474
24.3.4
Prognosis
.....................475
References
.............................475
25
Skin: Cutaneous Toxicities
Martina Nathan
·
Deborah Tomlinson
25.1
Alopecia
..........................477
25.1.1
Etiology
......................477
25.1.3
Treatment
....................478
25.1.4
Prognosis
.....................479
25.2
Altered Skin Integrity Associated
with Radiation Therapy
................479
25.2.1
Incidence
.....................479
25.2.2
Etiology
......................479
25.2.3
Prevention
....................479
25.2.4
Treatment
....................480
25.2.5
Prognosis
.....................481
25.3
Radiation Sensitivity and Recall
..........481
25.3.1
Incidence
.....................481
25.3.2
Etiology
......................481
25.3.3
Clinical Features
................481
25.3.4
Treatment
....................481
25.3.5
Prognosis
.....................482
25.4
Ultraviolet Recall Reaction/Photosensitivity.
.482
Contents
25.5
Cutaneous Reactions Associated
with High-Dose Cytosine Arabinoside
......482
25.5.1
Incidence
.....................482
25.5.2
Etiology
......................482
25.5.3
Prevention and Treatment
..........482
25.6
Nail Dystrophies
.....................483
25.7
Graft Vs. Host Disease
.................483
25.7.1
Incidence and Etiology
............483
25.7.2
Prevention
....................485
25.7.3
Treatment
....................486
25.7.4
Prognosis
.....................486
References
.............................486
26
Endocrine System
Julie Watson
26.1
Introduction
.......................489
26.2
Hypothalamic-Pituitary Dysfunction
.......489
26.2.1
Incidence and Etiology
............489
26.3
Growth Hormone Deficiency
............491
26.3.1
Treatment
....................492
26.3.2
Prognosis
.....................492
26.4
Hypothalamic-Pituitary-Gonadal Axis
.....493
26.4.1
Gonadotrophin Deficiency
..........493
26.4.2
Early or Precocious Puberty
.........493
26.5
Thyroid Disorders
....................494
26.5.1
Treatment
....................494
26.6
Hypothalamic-Pituitary-AdrenalAxis
......495
26.6.1
Treatment
....................495
26.7
Other Pituitary Hormones
..............495
26.7.1
Fertility
......................496
26.7.2
Treatment
....................496
26.7.3
Prognosis
.....................497
References
.............................499
27
Ototoxicity
Colleen Nixon
27.1
Introduction
.......................501
27.2
Prevention and Treatment
..............505
27.3
Future Perspectives
..................507
27.4
Prognosis
.........................508
References
.............................508
28.1.2
Prevention
....................512
28.1.3
Treatment
....................512
28.1.4
Prognosis
.....................512
28.2
Cataracts
..........................513
28.2.1
Incidence
.....................513
28.2.2
Etiology
......................513
28.2.3
Prevention
....................513
28.2.4
Treatment
....................513
28.2.5
Prognosis
.....................513
References
.............................513
PARTV
29
Nutrition and
Hydration in
Children
with Cancer
Cheryl Rodgers
·
Sara Gonzalez
29.1
Introduction
.......................515
29.2
Nutritional Assessment
................516
29.2.1 Hydration
Needs
................516
29.2.2
Nutrition Needs
.................516
29.2.3
Nutritional History
...............517
29.2.4
Physical Examination
.............518
29.2.5
Anthropométrie
Measurements
......518
29.2.6
Laboratory Evaluation
.............519
29.3
Principles of Treatment for Dehydration
and Malnutrition
....................519
29.3.1
Rehydration
...................519
29.3.2
Oral Nutrition Replacement
.........520
29.3.3
Enterai
Nutrition Replacement
.......520
29.3.4
Total Parenteral Nutrition/
Hyperalimentation
...............521
29.4
Special Considerations
................524
29.4.1
Common
Hydration
Complications
.... 524
29.4.2
Common Complications of Oral/Enteral
Nutritional Supplementation
........524
29.4.3
Common Complications of Total
Parenteral Nutrition/Hyperalimintation
. 525
29.4.4
Common Complications of
Enterai
and
Parenteral Nutritional Supplementation
. 527
29.4.5
Specific Nutritional Concerns
of Long-Term Survivors
............527
29.4.6
Specific Nutritional Concerns
During Palliative Care
.............527
References
.............................528
28
Ocular Complications
Martina Nathan
·
Deborah Tomlinson
28.1
Ocular
Toxicity
Associated with
High-Dose Cytarabine Arabinoside
........511
28.1.1
Incidence and Etiology
............511
30
Pain in Children with Cancer
Cara
Simon
30.1
Introduction
.......................529
30.2
Causes of Pain in Childhood Cancer
........529
Contents
30.3
Assessment
........................530
30.4
Cultural Issues
......................536
30.5
Principles of Treatment
................536
30.6
Treatment
.........................537
30.6.1
By the Ladder
..................537
30.6.2
BytheRoute
...................538
30.6.3
By the Clock
...................538
30.6.4
Opioids
......................538
30.6.5
Equianalgesia
..................538
30.6.6
Procedure-Related Pain
............540
30.6.7
Patient-Controlled Analgesia (PCA)
.... 540
30.6.8
Adjuvant Medications
.............542
30.6.9
Nonpharmacologic Treatment
.......542
References
.............................544
31
Blood Transfusion Therapy
Colleen Nixon
31.1
Introduction
.......................546
31.2
Blood Screening Guidelines
.............546
31.3
Blood Product Processing
..............546
31.3.1
Irradiation
....................547
31.3.2
Washed Red Blood Cells
...........547
31.4
Transfusion Complications
..............547
31.4.1
Hemolytic Reactions
..............547
31.4.2
Febrile NonhemolyticTransfusion
Reactions
.....................548
31.4.3
Allergic Reactions
...............548
31.4.4
Transfusion Associated Graft vs.
Host Disease
...................549
31.4.5
Circulatory Overload
..............549
31.4.6
Bacterial Contamination
...........549
31.4.7
Transfusion-Acquired Infections
......550
31.4.8
Iron Overload from Chronic
Transfusion
...................551
31.5
Red Blood Cell Transfusion
.............551
31.5.1
Packed Red Blood Cells
............551
31.5.2
Whole Blood
...................552
31.5.3
Exchange Transfusion
.............552
31.6
Platelet Transfusion
..................552
31.6.1
Indications
....................552
31.6.2
Procurement
..................553
31.6.3
Dosing/Transfusion Guidelines
.......553
31.6.4
Crossmatching
.................553
31.6.5
Nursing Implications
.............553
31.7
Granulocyte Transfusion
...............553
31.7.1
Indications
....................554
31.7.2
DosingATransfusion Guidelines
.......554
31.7.3
Crosssmatching
.................554
31.7.4
Nursing Implications
.............554
31.8
Albumin
(5
or
25%
solution) and Plasma
Protein Fraction
(5%
solution)
...........554
31.8.1
Indications
....................554
31.8.2
Dosing/Transfusion Guidelines
.......554
31.8.3
Crossmatching
.................555
31.8.4
Nursing Implications
.............555
31.9
Fresh Frozen Plasma
..................555
31.9.1
Indications
....................555
31.9.2
0оѕ тдДгапѕЛЈѕ 1ОП
Guidelines
.......555
31.9.3
Crossmatching
.................555
31.9.4
Nursing Implications
.............555
31.10
Cryopredpitate
.....................555
31.10.1
Indications
....................555
31.10.2
Dosing Guidelines
...............556
31.10.3
Crossmatching
.................556
31.10.4
Nursing Implications
.............556
31.11
Intravenous Immunoglobulin
............556
31.11.1
Indications
....................556
31.11.2
Оо5ІпдЯгап5йі5Іоп
Guidelines
.......556
31.11.3
Crossmatching
.................556
31.11.4
Nursing Implications
.............556
31.12
Erythropoietin
......................556
31.13
Indications
........................557
31.14
Dosing Guidelines
...................557
31.15
Nursing Implications
..................557
31.16
Palliative Care Issues for Transfusion Therapy
557
31.16.1
Anemia and Thrombocytopenia
......557
References
.............................557
32
Cytokines
Linda D Andrea
32.1
Principles of Treatment
................559
32.2
Future Perspectives
..................563
References
.............................564
33
Care of the Dying Child and the Family
Angela M. Ethier
33.1
Children s Understanding of Death
........565
33.1.1
Infants
(0-12
Months) and
Toddlers
(12-24
Months)
...........565
33.1.2
Preschool Children
(3-5
Years)
.......566
33.1.3
School-Age Children
(6-11
Years)
.....567
33.1.4
Adolescents
(12-19
Years)
..........567
33.2
Explaining Death to Children
............567
33.3
Pediatrie
Palliative Care
................568
33.3.1
Principles
.....................568
33.3.2
Locations of Care
................568
33.4
Grief
.............................569
33.4.1
Principles
.....................569
33.4.2
Assessment of Child and Family
......569
33.4.3
Interventions
..................571
33.5
Cultural and Spiritual Care
..............571
Contents
33.5.1
Principles
.....................571
33.5.2
Assessment of Child and
Family......571
33.5.3
Interventions
..................571
33.6
Nearing Death
......................573
33.6.1
Physical Symptoms Near the End of Life
573
33.6.2
Death-Related Sensory Experiences
.... 574
33.7
Care Following the Child s Death
.........575
33.7.1
Interventions Immediately Following the
Child s Death
..................575
33.7.2
Bereavement Interventions
.........575
33.8
Resources
.........................575
33.8.1
Resources for Children
............575
33.8.2
Resources for Adults
..............576
References
.............................576
Subject Index
579
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV035826352 |
| callnumber-first | R - Medicine |
| callnumber-label | RC281 |
| callnumber-raw | RC281.C4 |
| callnumber-search | RC281.C4 |
| callnumber-sort | RC 3281 C4 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | XH 2316 |
| ctrlnum | (OCoLC)505238428 (DE-599)DNB995195560 |
| dewey-full | 618.929940231 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 618 - Gynecology, obstetrics, pediatrics, geriatrics |
| dewey-raw | 618.929940231 |
| dewey-search | 618.929940231 |
| dewey-sort | 3618.929940231 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 2. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02010nam a2200553 c 4500</leader><controlfield tag="001">BV035826352</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20100111 </controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">091113s2010 gw ad|| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">09,N30,0634</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">995195560</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783540879831</subfield><subfield code="c">GB. : EUR 106.95 (freier Pr.), sfr 155.50 (freier Pr.)</subfield><subfield code="9">978-3-540-87983-1</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783540879831</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">12210930</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)505238428</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB995195560</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC281.C4</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">618.929940231</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 2316</subfield><subfield code="0">(DE-625)152878:12922</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pediatric oncology nursing</subfield><subfield code="b">advanced clinical handbook</subfield><subfield code="c">Deborah Tomlinson ... (eds.)</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin[u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXI, 584 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Child</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">nursing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nursing Care</subfield><subfield code="x">methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pediatric Nursing</subfield><subfield code="x">methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pediatric nursing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tumors in children</subfield><subfield code="x">Nursing</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kind</subfield><subfield code="0">(DE-588)4030550-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krankenpflege</subfield><subfield code="0">(DE-588)4032813-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Kind</subfield><subfield code="0">(DE-588)4030550-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Krankenpflege</subfield><subfield code="0">(DE-588)4032813-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tomlinson, Deborah</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018684989&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-018684989</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV035826352 |
| illustrated | Illustrated |
| indexdate | 2024-12-23T22:46:25Z |
| institution | BVB |
| isbn | 9783540879831 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-018684989 |
| oclc_num | 505238428 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XXI, 584 S. Ill., graph. Darst. |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Springer |
| record_format | marc |
| spellingShingle | Pediatric oncology nursing advanced clinical handbook Child Neoplasms nursing Nursing Care methods Pediatric Nursing methods Pediatric nursing Tumors in children Nursing Kind (DE-588)4030550-8 gnd Krebs Medizin (DE-588)4073781-0 gnd Krankenpflege (DE-588)4032813-2 gnd |
| subject_GND | (DE-588)4030550-8 (DE-588)4073781-0 (DE-588)4032813-2 (DE-588)4143413-4 |
| title | Pediatric oncology nursing advanced clinical handbook |
| title_auth | Pediatric oncology nursing advanced clinical handbook |
| title_exact_search | Pediatric oncology nursing advanced clinical handbook |
| title_full | Pediatric oncology nursing advanced clinical handbook Deborah Tomlinson ... (eds.) |
| title_fullStr | Pediatric oncology nursing advanced clinical handbook Deborah Tomlinson ... (eds.) |
| title_full_unstemmed | Pediatric oncology nursing advanced clinical handbook Deborah Tomlinson ... (eds.) |
| title_short | Pediatric oncology nursing |
| title_sort | pediatric oncology nursing advanced clinical handbook |
| title_sub | advanced clinical handbook |
| topic | Child Neoplasms nursing Nursing Care methods Pediatric Nursing methods Pediatric nursing Tumors in children Nursing Kind (DE-588)4030550-8 gnd Krebs Medizin (DE-588)4073781-0 gnd Krankenpflege (DE-588)4032813-2 gnd |
| topic_facet | Child Neoplasms nursing Nursing Care methods Pediatric Nursing methods Pediatric nursing Tumors in children Nursing Kind Krebs Medizin Krankenpflege Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018684989&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT tomlinsondeborah pediatriconcologynursingadvancedclinicalhandbook |